Search | IOVS | ARVO Journals

Showing 1 – 20 of 36

SORT: Best Match Most Recent Oldest

VIEW: Basic | Expanded

ARVO Annual Meeting Abstract June 2020

Longitudinal characterization of the Cln8 mnd mouse model of CLN8 Batten Disease.

Marc Cerrada-Gimenez; Giedrius Kalesnykas; Kimmo Lehtimäki; Timmo Bragge; Jukka Puoliväli; Jussi Rytkönen; Pekka Poutiainen; Tyler Johnson; Jacob Cain; Samantha Davis; Antti Nurmi; Jill Weimer

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):2240. doi:

ARVO Annual Meeting Abstract June 2020

Xanthohumol protects corneal epithelial cells in experimental models for dry-eye disease

Anita K. Ghosh; Rubina Thapa; Harsh Nilesh Hariani; Agne Ziniauskaite; Samatha Ankireddy; Karoline A Orloff; Jenni J. Hakkarainen; Giedrius Kalesnykas; Kelly Langert; Simon Kaja

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):3257. doi:

ARVO Annual Meeting Abstract June 2020

Automated quantification of CNV volume using deep learning AI algorithm

Maria Vähätupa; Symantas Ragauskas; Agne Ziniauskaite; Anna Knuuttila; Hanna-Kaisa Sihvo; Mikael Jääskeläinen; Simon Kaja; Giedrius Kalesnykas; Marc Cerrada-Gimenez

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):4194. doi:

ARVO Annual Meeting Abstract June 2020

Comparative efficacy of bevacizumab and aflibercept in the rabbit DL-AAA model of chronic retinal neovascularization

Robertas Cesna; Tomas Paulauskas; Kernius Mickevicius; Donatas Neverauskas; Inesa Lelyte; Simon Kaja; Giedrius Kalesnykas; Symantas Ragauskas

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):5391. doi:

ARVO Annual Meeting Abstract June 2020

Characterization of VEGF-induced retinal neovascularization in Dutch Belted rabbits using in vivo imaging.

Donatas Neverauskas; Kernius Mickevičius; Simon Kaja; Giedrius Kalesnykas; Symantas Ragauskas

Invest. Ophthalmol. Vis. Sci.. 2020; 61(7):5399. doi:

ARVO Annual Meeting Abstract July 2019

Comparison and validation of ex vivo and in vitro corneal permeability models

Jenni J. Hakkarainen; Agne Ziniauskaite; Vytautas Cepla; Ramunas Valiokas; Giedrius Kalesnykas

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):5087. doi:

ARVO Annual Meeting Abstract July 2019

Standardization and validation of intravitreal and systemic administration of aflibercept in preclinical models for angiogenesis

Simon Kaja; Symantas Ragauskas; Maria Vähätupa; Marc Cerrada-Gimenez; Satu Mering; Jenni J. Hakkarainen; Giedrius Kalesnykas

Invest. Ophthalmol. Vis. Sci.. 2019; 60(9):1629. doi:

Retina May 2019

Viability of Mouse Retinal Explant Cultures Assessed by Preservation of Functionality and Morphology

PDF

Virpi Alarautalahti; Symantas Ragauskas; Jenni J. Hakkarainen; Hannele Uusitalo-Järvinen; Hannu Uusitalo; Jari Hyttinen; Giedrius Kalesnykas; Soile Nymark
TAGS: language morphology, mice, morphology, retina, tissue preparation, photoreceptors
Invest. Ophthalmol. Vis. Sci.. 2019; 60(6):1914-1927. doi: https://doi.org/10.1167/iovs.18-25156

ARVO Annual Meeting Abstract July 2018

Combining ISTH0036, an antisense oligonucleotide targeting Transforming Growth Factor beta 2 (TGF-β2) mRNA, with aflibercept as novel treatment strategy for neovascular retinal diseases

Michel Janicot; Giedrius Kalesnykas; Eugen Leo; Petra Fettes; Simon Kaja; Katja Wosikowski

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):236. doi:

ARVO Annual Meeting Abstract July 2018

Aflibercept shows strong dose-dependency when administered intravitreally in the mouse CNV model

Ruta Maciulaitiene; Symantas Ragauskas; Anna Mari Haapaniemi; Simon Kaja; Ingrida Januleviciene; Giedrius Kalesnykas

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2631. doi:

ARVO Annual Meeting Abstract July 2018

Utility of approved dry-eye drugs as reference compounds in SiccaSystem TM - a standardized mouse desiccating stress model for dry-eye disease

Simon Kaja; Symantas Ragauskas; Agne Ziniauskaite; Anna Mari Haapaniemi; Jenni J. Hakkarainen; Henna Martiskainen; Giedrius Kalesnykas

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):2673. doi:

ARVO Annual Meeting Abstract July 2018

Neuroprotection of retinal ganglion cells via NMDA-dependent mechanism in the mouse non-arteritic anterior ischemic optic neuropathy (NAION) model

Symantas Ragauskas; Agne Ziniauskaite; Simon Kaja; Giedrius Kalesnykas

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3204. doi:

ARVO Annual Meeting Abstract July 2018

Pre-clinical efficacy of OCU300 nanoemulsion for the treatment of ocular graft versus host disease (oGVHD).

Rasappa Arumugham; Gopalam Somasekhar; Arun K Upadhyay; Giedrius Kalesnykas; Simon Kaja; Sandeep Jain

Invest. Ophthalmol. Vis. Sci.. 2018; 59(9):3287. doi:

Cornea June 2018

Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome

PDF

Agnė Žiniauskaitė; Symantas Ragauskas; Jenni J. Hakkarainen; Cadmus C. Rich; Rudolf Baumgartner; Giedrius Kalesnykas; David S. Albers; Simon Kaja
TAGS: cyclosporine, dry eye syndromes, eye, keratoconjunctivitis sicca, mice, pathology, syndrome, conjunctiva, goblet cells, cornea
Invest. Ophthalmol. Vis. Sci.. 2018; 59(7):3088-3093. doi: https://doi.org/10.1167/iovs.18-24432

ARVO Annual Meeting Abstract June 2017

Targeting Transforming Growth Factor beta 2 (TGF-β2) mRNA with ISTH0036 as Novel Therapeutic Intervention in Neovascular Ocular Disease

Katja Wosikowski; Inge van Hoven; Jooseppi Puranen; Lies de Groef; Anne Mari Haapaniemi; Jurgen Sergeys; Simon Kaja; Giedrius Kalesnykas; Lieve K M Moons; Michel Janicot

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):1948. doi:

ARVO Annual Meeting Abstract June 2017

Assessment of the effects of systemically administered levetiracetam in an ocular model for neuroprotection.

Ruta Maciulaitiene; Symantas Ragauskas; Giedre Pakuliene; Simon Kaja; Ingrida Januleviciene; Giedrius Kalesnykas

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):2571. doi:

ARVO Annual Meeting Abstract June 2017

Development of an artificial cornea for testing drug candidate permeability in early stages of drug development

Jenni J. Hakkarainen; Vytautas Cepla; Agne Ziniauskaite; Ramunas Valiokas; Giedrius Kalesnykas

Invest. Ophthalmol. Vis. Sci.. 2017; 58(8):4337. doi:

ARVO Annual Meeting Abstract September 2016

hiPSC-derived RPE cells: Characterization of blood-retinal barrier properties and drug permeability

Jenni J. Hakkarainen; Julien Maruotti; Aila Seppänen; Brigitte Onteniente; Giedrius Kalesnykas; Mika Reinisalo

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):268. doi:

ARVO Annual Meeting Abstract September 2016

Age-related differences in light sensitivity in BALB/c mice

Giedrius Kalesnykas; Symantas Ragauskas; Simon Kaja; Heikki Tanila; Henri Olavi Leinonen

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5004. doi:

ARVO Annual Meeting Abstract September 2016

Subretinal injection of poly(IC) causes acute photoreceptor cell death in the mouse retinal detachment model

Symantas Ragauskas; Sabine Grüner; Ludovic Collin; Giedrius Kalesnykas

Invest. Ophthalmol. Vis. Sci.. 2016; 57(12):5377. doi:

1 2

Next 20 Results »

NARROW

Content Type

Journal

Article Type

Topics

Tags

Specify Date Range

Longitudinal characterization of the Cln8 mnd mouse model of CLN8 Batten Disease.

Xanthohumol protects corneal epithelial cells in experimental models for dry-eye disease

Automated quantification of CNV volume using deep learning AI algorithm

Comparative efficacy of bevacizumab and aflibercept in the rabbit DL-AAA model of chronic retinal neovascularization

Characterization of VEGF-induced retinal neovascularization in Dutch Belted rabbits using in vivo imaging.

Comparison and validation of ex vivo and in vitro corneal permeability models

Standardization and validation of intravitreal and systemic administration of aflibercept in preclinical models for angiogenesis

Viability of Mouse Retinal Explant Cultures Assessed by Preservation of Functionality and Morphology

Combining ISTH0036, an antisense oligonucleotide targeting Transforming Growth Factor beta 2 (TGF-β2) mRNA, with aflibercept as novel treatment strategy for neovascular retinal diseases

Aflibercept shows strong dose-dependency when administered intravitreally in the mouse CNV model

Utility of approved dry-eye drugs as reference compounds in SiccaSystem TM - a standardized mouse desiccating stress model for dry-eye disease

Neuroprotection of retinal ganglion cells via NMDA-dependent mechanism in the mouse non-arteritic anterior ischemic optic neuropathy (NAION) model

Pre-clinical efficacy of OCU300 nanoemulsion for the treatment of ocular graft versus host disease (oGVHD).

Efficacy of Trabodenoson in a Mouse Keratoconjunctivitis Sicca (KCS) Model for Dry-Eye Syndrome

Targeting Transforming Growth Factor beta 2 (TGF-β2) mRNA with ISTH0036 as Novel Therapeutic Intervention in Neovascular Ocular Disease

Assessment of the effects of systemically administered levetiracetam in an ocular model for neuroprotection.

Development of an artificial cornea for testing drug candidate permeability in early stages of drug development

hiPSC-derived RPE cells: Characterization of blood-retinal barrier properties and drug permeability

Age-related differences in light sensitivity in BALB/c mice

Subretinal injection of poly(IC) causes acute photoreceptor cell death in the mouse retinal detachment model

To View More...

You must be signed into an individual account to use this feature.